Repare Therapeutics reports Q1 net income $13.2M; FDA agrees on RP2D for lunresertib+camonsertib combination

Repare Therapeutics Inc.

2024-Q1 EPS reported $0.30

Net income of $13.2M ($0.30 diluted) vs loss of $34.9M a year ago; revenue $52.4M primarily from $40M Roche milestone.
Cash, equivalents and marketables $237M, sufficient to fund operations at least into mid-2026.
FDA agreed to RP2D for lunresertib 80mg BID + camonsertib 80mg QD; Grade 3 anemia reduced to 25% from 45%.
Regained global rights to camonsertib from Roche; cumulative $182.6M received from Roche under collaboration.
First patient dosed in Phase 1 LIONS trial of PLK4 inhibitor RP-1664; expecting pivotal trial start for lunresertib combo in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Repare Therapeutics Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Repare Therapeutics Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the three months ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-054486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.